Citi raised the firm’s price target on Caris Life Sciences (CAI) to $42 from $34 and keeps a Buy rating on the shares. The firm views Caris Life’s first quarter as a public company as strong and lifted estimates post the print.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences Reports Strong Q2 2025 Results
- Strong Performance and Growth Potential: Caris Life Sciences, Inc. Receives Buy Rating with Increased Price Target
- Closing Bell Movers: CoreWeave down 10% despite revenue beat, guidance raise
- Caris Life Sciences reports Q2 EPS ($7.97) with items, consensus (22c)
- Caris Life Sciences sees FY25 revenue $675.0M-$685.0M, consensus $588M